Epinephrin-Flüssigformulierungen
EP4755371
10. Juni 2026
Anmelder: Fresenius Kabi USA, LLC 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4755371
- Anmeldetag
- 8. Dezember 2025
- Veröffentlichung
- 10. Juni 2026
- Rechtsraum
- EP
Abstract
The invention provides a stable, pharmaceutical formulation comprising epinephrine or a pharmaceutically acceptable salt thereof. The formulation includes an organic acid, a tonicity agent, and water, has a pH of about 3.0 to about 3.6, and is substantially free of a conjugate base of the organic acid.
Anmelder
- Firma
- Fresenius Kabi USA, LLC
- Land
- 🇺🇸 USA